“Non-criteria antiphospholipid antibodies”: bridging the gap between seropositive and seronegative Antiphospholipid Syndrome.

Bookmark this %label%

We aimed to analyze the prevalence of non-criteria anti-phospholipid (aPL) antibodies and their role in the diagnosis, treatment and prognosis in a cohort of patients with clinical features consistent with […]

» Read more

Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.

Bookmark this %label%

The FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) trial assessed efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin in patients with knee osteoarthritis. Here, […]

» Read more

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.

Bookmark this %label%

To better understand the factors that influence the humoral immune response to vaccination against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs).Patients and controls from a large COVID-19 study, with […]

» Read more

Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).

Bookmark this %label%

The objective of COAST-Y was to evaluate the effect of continuing versus withdrawing ixekizumab (IXE) in patients with axial spondyloarthritis (axSpA) who had achieved remission.COAST-Y is an ongoing, phase III, […]

» Read more

Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry.

Bookmark this %label%

To investigate survival of interleukin (IL)-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective.Multicentre retrospective […]

» Read more

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial.

Bookmark this %label%

To compare the benefits of a tight-control/treat-to-target strategy (TC/T2T) in axial spondyloarthritis (axSpA) with those of usual care (UC).Pragmatic, prospective, cluster-randomised, controlled, open, 1-year trial (NCT03043846). 18 centres were randomised […]

» Read more

Phase 2, Randomized, Placebo-Controlled Trial of Dapirolizumab Pegol in Patients with Moderate-to-Severe Active Systemic Lupus Erythematosus.

Bookmark this %label%

To evaluate dose-response, efficacy and safety of dapirolizumab pegol (DZP) in patients with systemic lupus erythematosus (SLE).Adults with moderately to severely active SLE (SLEDAI-2K score ≥6 and ≥1 BILAG A […]

» Read more

Abdominal arterial lesions associated with antiphospholipid antibodies: A comparative cross sectional magnetic resonance angiography study.

Bookmark this %label%

Case reports and small case series suggest that stenotic lesions of the renal, coeliac and mesenteric arteries may occur in the antiphospholipid syndrome (APS) resulting in clinical consequences such as […]

» Read more

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

Bookmark this %label%

Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy […]

» Read more

The synergistic efficacy of hydroxychloroquine with methotrexate is accompanied by increased erythrocyte mean corpuscular volume.

Bookmark this %label%

To determine whether concomitant hydroxychloroquine modulates the increase in erythrocyte mean corpuscular volume (MCV) caused by methotrexate therapy, and whether this is associated with improved clinical response in rheumatoid arthritis […]

» Read more

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.

Bookmark this %label%

Sustained remission has become an achievable goal for patients with rheumatoid arthritis (RA) receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), but how to best treat patients in clinical remission remains […]

» Read more

Impact of coping strategies on patient and physician perceptions of disease severity and disability in systemic sclerosis.

Bookmark this %label%

Systemic sclerosis (SSc) results in impaired function, disability, and reduced health-related quality of life (HRQL). We investigated the impact of coping strategies on the patient global assessment of health (PtGA) […]

» Read more

Pooled Safety Results Through One Year of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis.

Bookmark this %label%

Evaluate safety of guselkumab (monoclonal antibody targeting IL-23p19) in psoriatic arthritis (PsA) patients through 1year (1Y) of the Phase-3 DISCOVER-1&2 trials.Patients with active PsA (N=1120; biologic-naïve except the118 TNFi-treated DISCOVER-1 […]

» Read more

Predicting Response to Tocilizumab Monotherapy in Rheumatoid Arthritis: A Real-World Data Analysis Using Machine Learning.

Bookmark this %label%

Tocilizumab (TCZ) had similar efficacy when used as monotherapy or in combination with other treatments for rheumatoid arthritis (RA) in randomized controlled trials (RCT). We derived a remission prediction score […]

» Read more
1 2 3 88